{
  "asset": {
    "name": "KT-485",
    "alternate_names": [
      "SAR447971"
    ],
    "company": "Kymera Therapeutics",
    "partner": "Sanofi",
    "ticker": "KYMR",
    "target": "IRAK4",
    "target_full_name": "Interleukin-1 Receptor Associated Kinase 4",
    "mechanism": "IRAK4 degrader (targeted protein degradation)",
    "modality": "Oral small molecule degrader",
    "pathway": "IL-1R/TLR/MyD88 signaling",
    "generation": "Second-generation (improved over KT-474)"
  },
  "clinical_development": {
    "current_stage": "IND-Enabling (Phase 1 expected 2026)",
    "indications_in_development": [
      "Hidradenitis Suppurativa (HS)",
      "Atopic Dermatitis (AD)",
      "Rheumatoid Arthritis (RA)",
      "Asthma",
      "Inflammatory Bowel Disease (IBD)"
    ],
    "market_opportunity": ">140M patients; systemic advanced therapies reach only 3%; >$55B market opportunity"
  },
  "target_biology": {
    "description": "IRAK4 is a master regulator of innate immunity with both scaffolding and kinase functions.\nIt is an obligate node in IL-1R/TLR signaling. IRAK4 degradation is the only approach to fully block the pathway.",
    "genetic_validation": "Adult humans with IRAK4 null mutation are healthy",
    "pathway_validation": [
      "IL-1\u03b1/IL-1\u03b2 validated in RA, CAPS, HS, AD, RP, Gout",
      "IL-18 validated in AD, Macrophage Activation Syndrome",
      "IL-36 validated in Generalized Pustular Psoriasis",
      "IL-33 validated in Asthma, COPD",
      "IRAK4 SMI showed activity in RA"
    ],
    "degrader_advantage": "Degradation eliminates both scaffolding AND kinase functions - more complete pathway blockade than kinase inhibitors"
  },
  "differentiation_vs_kt474": {
    "description": "KT-485 is a second-generation IRAK4 degrader with improvements over KT-474",
    "improvements": [
      "Increased selectivity",
      "Increased potency",
      "Absence of any QTc signal (cardiac safety improvement)",
      "Prioritized by Sanofi for clinical development over KT-474"
    ]
  },
  "partnership": {
    "partner": "Sanofi",
    "structure": "Sanofi to advance KT-485 into Phase 1 and subsequent development",
    "economics": "Kymera receives milestones and royalties",
    "status": "Sanofi expected to initiate Phase 1 in 2026",
    "learnings": "Clinical learnings from KT-474 studies will accelerate KT-485 development"
  },
  "trials": [
    {
      "name": "KT-485 Phase 1 Study",
      "phase": "Phase 1",
      "status": "Expected to initiate 2026",
      "sponsor": "Sanofi",
      "indication": "TBD (likely HS or AD based on KT-474 experience)",
      "notes": "Sanofi leading development; Kymera provides support"
    }
  ],
  "investment_thesis": [
    "Second-generation IRAK4 degrader with improved profile over KT-474",
    "Partnered with Sanofi - validates platform and provides development capital",
    "Potential combined activity of multiple upstream biologics (anti-IL-1/18/33/36) in oral pill",
    "KT-474 clinical learnings de-risk KT-485 development",
    "No QTc signal - addresses key safety concern for IRAK4 inhibitors",
    "Large market: >140M patients across HS, AD, RA, asthma, IBD",
    "IRAK4 null humans are healthy - genetic validation for safety"
  ],
  "key_risks": [
    "Dependent on Sanofi for clinical development execution",
    "KT-474 development discontinued in favor of KT-485 - limited human data",
    "IRAK4 degradation is novel mechanism - clinical validation needed",
    "Competitive landscape includes JAK inhibitors, IL-1/IL-36 antibodies",
    "HS is a difficult indication with high placebo response"
  ],
  "upcoming_catalysts": [
    {
      "event": "Sanofi Phase 1 initiation",
      "timing": "2026"
    },
    {
      "event": "Phase 1 safety/PK data",
      "timing": "2027"
    }
  ]
}